Global E-Health Forum: Designing Personalized Healthcare

11 - 13 October 2011, Hamburg, Germany.
Dr. Eric M. Liederman (Director of Medical Informatics, The Permanente Medical Group, U.S.A.) has confirmed his keynote at this year's Global E-Health Forum. He will present "Balancing Privacy Protection with Patient Care".

Healthcare organizations are under increasing regulatory pressure to improve the quality and safety of care and to protect patient privacy. Electronic Health Records (EHR) provide a vehicle to improve care, however concerns over protecting the system against privacy violations are a significant challenge. Dr. Eric Liederman will discuss how to achieve a balance between protecting privacy and security, and fostering high quality patient care.

Learn how Kaiser Permanente's "trust, but hold accountable" approach using forensic mining of its EHR audit databases, resulted in a > 90% reduction in privacy violations over several weeks. Learn how deterrence methods have also helped clinicians and staff avoid giving in to career-ending temptation.

Canada is Partner Country
Mr. Peter M. Boehm, Ambassador of Canada in Germany is pleased to endorse the Global E-Health Forum in Hamburg. He states: "Developing successful e-health solutions requires combining knowledge and technology in several key areas, including: enabling electronic communications infrastructure; providing remote communities in Canada with access to clinical and non-clinical healthcare professionals through the use of advanced information communications technologies; improving health information systems to support service delivery including virtual health libraries; and upholding the health privacy of patients through high standards of information management and exchange." For full text, please see http://www.global-ehealth-forum.com/canada/.

Transforming healthcare in Canada through e-health, the challenges facing the health system in Canada and the role of information and information technology within a reformed health system - these are the topics Richard C. Alvarez, President and Chief Executive Officer, Canada Health Infoway, will address in his keynote.

Program
The first two conference days at the Hamburg Chamber of Commerce will feature more speakers from all over the globe. Their strategy presentations and case studies will be complemented by discussion forums, workshops and an exhibition of solution providers. The official reception for the conference delegates will take place in the U.S. Consulate General ("the little White House at the lake Alster") on October 11. The third day is dedicated to various breakout sessions and guided tours at different locations (among others hospitals) targeting the individual information needs of special interest groups.

Registration
Register by August 30 for a conference fee of Euro 599 incl. VAT. The fee includes the admission to all conference sessions, lunches, coffee breaks and the evening reception on October 11, 2011.

For further information, please visit:
http://www.global-ehealth-forum.com

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...